• Continuous strap feed: The strap feeds through the device without excess slack, eliminating the "gap" between the tourniquet and the limb that costs precious seconds in windlass designs .
• One-handed self-application: The wounded person can operate it with one hand, allowing them to stay in the fight or self-evacuate .
• Wider strap (48–50 mm): Distributes pressure more evenly, reducing the force needed to occlude blood flow and decreasing pain and tissue damage .
• Repeatable pull-cord engagement: Users can pull multiple times to remove any remaining slack after initial securing .

The device is compact at 40 mm × 89 mm × 80 mm and targets a ten-year shelf life .

Role of the Norwegian Armed Forces and FFI

The Norwegian Defence Research Establishment (FFI) has been involved since the concept stage. Aristeia states it has worked closely with FFI since first developing the idea, with all prototyping done at FFI's advanced workshop at Kjeller and pre-clinical trials administered by FFI's Comprehensive Defence Division . The Norwegian Armed Forces also participated through an industry development program of the Royal Norwegian Ministry of Defence, which recognized the tourniquet's wider potential and turned the idea into a formal joint project .

Why a Purely Mechanical Design?

The founders — Gard Fostad Moe (a physicist and former military service member) and Hsin Chen (a health economist) — intentionally chose a purely mechanical, pull-cord design rather than a sensor-equipped or electronic tourniquet. Moe has stated he wanted a device that requires "minimal strength for operation" and works reliably in the harshest battlefield conditions — where sensors might fail, batteries die, or electronics get damaged . The core philosophy is simplicity: intuitive, on-device instructions, no electronics, and a design that works every time, even under extreme stress or in wet, muddy, cold environments .

Civilian Applications: The AED Parallel

Aristeia explicitly expects the civilian market to eventually overtake the military market in volume . Moe draws a parallel to automated external defibrillators (AEDs): just as AEDs are now placed in public spaces and carried by trained civilians, Aristeia envisions its tourniquet becoming a ubiquitous life-saving tool in schools, offices, vehicle first-aid kits, and public venues . The company highlights that ordinary Ukrainians now carry tourniquets daily due to the risk of bombings and drone strikes, and sees a similar model for civilian preparedness in peacetime .

Manufacturing and Scaling Challenges

Aristeia faces several key hurdles as it moves toward commercialization:

• Production volumes: The company has struggled to produce sufficient units for field evaluation; this bottleneck is only now clearing as it scales manufacturing meaningfully for the first time .
• Relocation considerations: Aristeia is actively exploring relocating operations abroad to better support scaling, though specific locations have not been announced .
• Ukraine technology transfer: The Ukrainian government approached the company through its embassy in Oslo in 2022. Aristeia is committed to supplying hundreds of units and is exploring technology transfer to enable production inside Ukraine itself .
• Competitive pricing: While no final price point has been set, the company has invested heavily in driving down production costs to remain competitive with existing tourniquets .
• Pre-commercialization status: The device is still in pre-commercialization, though field feedback has been gathered from earlier generations used in Ukraine .

• Continuous strap feed: The strap feeds through the device without excess slack, eliminating the "gap" between the tourniquet and the limb that costs precious seconds in windlass designs .
• One-handed self-application: The wounded person can operate it with one hand, allowing them to stay in the fight or self-evacuate .
• Wider strap (48–50 mm): Distributes pressure more evenly, reducing the force needed to occlude blood flow and decreasing pain and tissue damage .
• Repeatable pull-cord engagement: Users can pull multiple times to remove any remaining slack after initial securing .

The device is compact at 40 mm × 89 mm × 80 mm and targets a ten-year shelf life .

Role of the Norwegian Armed Forces and FFI

The Norwegian Defence Research Establishment (FFI) has been involved since the concept stage. Aristeia states it has worked closely with FFI since first developing the idea, with all prototyping done at FFI's advanced workshop at Kjeller and pre-clinical trials administered by FFI's Comprehensive Defence Division . The Norwegian Armed Forces also participated through an industry development program of the Royal Norwegian Ministry of Defence, which recognized the tourniquet's wider potential and turned the idea into a formal joint project .

Why a Purely Mechanical Design?

The founders — Gard Fostad Moe (a physicist and former military service member) and Hsin Chen (a health economist) — intentionally chose a purely mechanical, pull-cord design rather than a sensor-equipped or electronic tourniquet. Moe has stated he wanted a device that requires "minimal strength for operation" and works reliably in the harshest battlefield conditions — where sensors might fail, batteries die, or electronics get damaged . The core philosophy is simplicity: intuitive, on-device instructions, no electronics, and a design that works every time, even under extreme stress or in wet, muddy, cold environments .

Civilian Applications: The AED Parallel

Aristeia explicitly expects the civilian market to eventually overtake the military market in volume . Moe draws a parallel to automated external defibrillators (AEDs): just as AEDs are now placed in public spaces and carried by trained civilians, Aristeia envisions its tourniquet becoming a ubiquitous life-saving tool in schools, offices, vehicle first-aid kits, and public venues . The company highlights that ordinary Ukrainians now carry tourniquets daily due to the risk of bombings and drone strikes, and sees a similar model for civilian preparedness in peacetime .

Manufacturing and Scaling Challenges

Aristeia faces several key hurdles as it moves toward commercialization:

• Production volumes: The company has struggled to produce sufficient units for field evaluation; this bottleneck is only now clearing as it scales manufacturing meaningfully for the first time .
• Relocation considerations: Aristeia is actively exploring relocating operations abroad to better support scaling, though specific locations have not been announced .
• Ukraine technology transfer: The Ukrainian government approached the company through its embassy in Oslo in 2022. Aristeia is committed to supplying hundreds of units and is exploring technology transfer to enable production inside Ukraine itself .
• Competitive pricing: While no final price point has been set, the company has invested heavily in driving down production costs to remain competitive with existing tourniquets .
• Pre-commercialization status: The device is still in pre-commercialization, though field feedback has been gathered from earlier generations used in Ukraine .